Sort   by:  
 Page size 
MetabolomicsMetabolic Reprogramming in Tumor-Associated Macrophages during Murine Hepatocellular Carcinoma Progression

To investigate the impact of Wdr4 on the metabolic reprogramming of tumor-associated macrophages (TAMs) in hepatocellular carcinoma (HCC), we established an orthotopic HCC model in Wdr4-f/f and Wdr4 conditional knockout (Wdr4-cKO) mice. TAMs were subsequently isolated via flow cytometry-based cel...

2025-09-28 | MTBLS12764 | MetaboLights
MetabolomicsLC−MS Based Serum Metabolomics for Identification of Hepatocellular Carcinoma Biomarkers in Egyptian Cohort
Although hepatocellular carcinoma (HCC) has been subjected to continuous investigation and its symptoms are well-known, early stage diagnosis of this disease remains difficult and the survival rate after diagnosis is typically very low (3−5%). Early and accurate detection of metabolic changes in the...
2013-06-30 | MTBLS19 | MetaboLights
MetabolomicsUtilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis
Characterizing the metabolic changes pertaining to hepatocellular carcinoma (HCC) in patients with liver cirrhosis is believed to contribute towards early detection, treatment, and understanding of the molecular mechanisms of HCC. In this study, we compare metabolite levels in sera of 78 HCC cases w...
MTBLS17 | MetaboLights
MetabolomicsLiver-specific paraoxonase-1 alleviates regulatory T cell-driven immunosuppression via metabolic reprogramming in hepatocellular carcinoma

Paraoxonase-1 (PON1) is specifically expressed in the liver and has crucial effects on various liver diseases. The functions and mechanisms underlying of PON1 in hepatocellular carcinoma (HCC) remain obscure. Here, we show that PON1 acts as a metabolic regulator to mitigate regulatory T (Treg) ce...

2025-09-07 | MTBLS12950 | MetaboLights
MetabolomicsPlasma metabolomic profiling for hepatocellular carcinoma diagnosis and microvascular invasion prediction
Altered metabolites play a crucial role in the development and progression of hepatocellular carcinoma (HCC). In this study, an untargeted metabolomic analysis was conducted to identify novel biomarkers with high sensitivity and specificity for the early detection of HCC and to explore their functio...
2025-07-02 | MTBLS11996 | MetaboLights
MetabolomicsSerum proteomics and metabolomics reveal novel noninvasive molecular signatures for hepatocellular carcinoma diagnosis
This study aimed to identify and validate noninvasive serum protein and metabolite biomarkers for the early detection and prognostic assessment of hepatocellular carcinoma (HCC).In this study, we systematically analyzed serum proteomics and metabolomics across four cohorts, including healthy control...
2026-04-10 | MTBLS14248 | MetaboLights
MetabolomicsCHML regulates migration and invasion in hepatocellular carcinoma via transcriptional and metabolic reprogramming

Hepatocellular carcinoma (HCC), a prevalent malignant neoplasm, presents significant therapeutic challenges. However, the key factors and mechanisms driving HCC metastasis remain incompletely understood. This study aimed to elucidate the mechanism through which CHML regulates the migration and in...

2025-07-28 | MTBLS12789 | MetaboLights
MetabolomicsGC-MS Based Plasma Metabolomics for Identification of Candidate Biomarkers for Hepatocellular Carcinoma in Egyptian Cohort
This study evaluates changes in metabolite levels in hepatocellular carcinoma (HCC) cases vs. patients with liver cirrhosis by analysis of human blood plasma using gas chromatography coupled with mass spectrometry (GC-MS). Untargeted metabolomic analysis of plasma samples from participants recruited...
2015-08-13 | MTBLS105 | MetaboLights
MetabolomicsMetabolomics biomarkers of hepatocellular carcinoma in a prospective cohort of patients with cirrhosis

BACKGROUND & AIMS: The effectiveness of surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis is limited, due to inadequate risk stratification and suboptimal performance of current screening modalities.

METHODS: We developed a mult...

2024-05-09 | MTBLS8764 | MetaboLights
MetabolomicsM3-Driven Hexosamine Biosynthesis Facilitates Hepatocellular Carcinoma Progression through YBX1 O-GlcNAcylation
Phosphoglucomutase 3 (PGM3) is one of the rate-limiting enzymes in the hexosamine biosynthesis pathway (HBP) and a key regulator of HBP metabolic flux. Despite the functional role of PGM3 has been validated in various tumors, its function and molecular mechanism in hepatocellular carcinoma (HCC) rem...
2026-09-04 | MTBLS15552 | MetaboLights
Sort   by:  
 Page size